Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
M Wetzler, … , M Beran, R Kurzrock
M Wetzler, … , M Beran, R Kurzrock
Published October 1, 1993
Citation Information: J Clin Invest. 1993;92(4):1925-1939. https://doi.org/10.1172/JCI116786.
View: Text | PDF
Research Article Article has an altmetric score of 6

Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.

  • Text
  • PDF
Abstract

We used specific antisera and immunohistochemical methods to investigate the subcellular localization and expression of Bcr, Abl, and Bcr-Abl proteins in leukemic cell lines and in fresh human leukemic and normal samples at various stages of myeloid differentiation. Earlier studies of the subcellular localization of transfected murine type IV c-Abl protein in fibroblasts have shown that this molecule resides largely in the nucleus, whereas transforming deletion variants are localized exclusively in the cytoplasm. Here, we demonstrate that the murine type IV c-Abl protein is also found in the nucleus when overexpressed in a mouse hematopoietic cell line. However, in both normal and leukemic human hematopoietic cells, c-Abl is discerned predominantly in the cytoplasm, with nuclear staining present, albeit at a lower level. In contrast, normal endogenous Bcr protein, as well as the aberrant p210BCR-ABL and p190BCR-ABL proteins consistently localize to the cytoplasm in both cell lines and fresh cells. The results with p210BCR-ABL were confirmed in a unique Ph1-positive chronic myelogenous leukemia (CML) cell line, KBM5, which lacks the normal chromosome 9 and hence the normal c-Abl product. Because the p210BCR-ABL protein appears cytoplasmic in both chronic phase and blast crisis CML cells, as does the p190BCR-ABL in Ph1-positive acute leukemia, a change in subcellular location of Bcr-Abl proteins between cytoplasm and nucleus cannot explain the different spectrum of leukemias associated with p210 and p190, nor the transition from the chronic to the acute leukemia phenotype seen in CML. Further analysis of fresh CML and normal hematopoietic bone marrow cells reveals that p210BCR-ABL, as well as the normal Bcr and Abl proteins, are expressed primarily in the early stages of myeloid maturation, and that levels of expression are reduced significantly as the cells mature to polymorphonuclear leukocytes. Similarly, a decrease in Bcr and Abl levels occurs in HL-60 cells induced by DMSO to undergo granulocytic differentiation. The action of p210BCR-ABL and its normal counterparts may, therefore, take place during the earlier stages of myeloid development.

Authors

M Wetzler, M Talpaz, R A Van Etten, C Hirsh-Ginsberg, M Beran, R Kurzrock

×

Total citations by year

Year: 2024 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1987 Total
Citations: 2 1 1 2 2 2 3 3 4 4 2 3 9 3 3 9 6 7 8 4 4 7 6 5 7 9 11 3 3 4 1 138
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (138)

Title and authors Publication Year
The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia
Zheng R, Wei W, Liu S, Zeng D, Yang Z, Tang J, Tan J, Huang Z, Gao M
Cell communication and signaling : CCS 2024
Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance
Eshaq AM, Flanagan TW, Hassan SY, Al Asheikh SA, Al-Amoudi WA, Santourlidis S, Hassan SL, Alamodi MO, Bendhack ML, Alamodi MO, Haikel Y, Megahed M, Hassan M
Cancers 2024
SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia.
Brown LM, Hediyeh-Zadeh S, Sadras T, Huckstep H, Sandow JJ, Bartolo RC, Kosasih HJ, Davidson NM, Schmidt B, Bjelosevic S, Johnstone R, Webb AI, Khaw SL, Oshlack A, Davis MJ, Ekert PG
Blood Advances 2022
Advances in Precision Medicine Oncology
H Arnouk, BA Hassan
2021
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes
J Stetka, J Gursky, JL Velasquez, R Mojzikova, P Vyhlidalova, L Vrablova, J Bartek, V Divoky
Cancers 2020
Identification of Phosphate-Containing Compounds as New Inhibitors of 14-3-3/c-Abl Protein–Protein Interaction
L Iralde-Lorente, G Tassone, L Clementi, L Franci, CC Munier, Y Cau, M Mori, M Chiariello, A Angelucci, MW Perry, C Pozzi, S Mangani, M Botta
ACS chemical biology 2020
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
L Bavaro, M Martelli, M Cavo, S Soverini
International journal of molecular sciences 2019
The interaction between PLEKHG2 and ABL1 suppresses cell growth via the NF-κB signaling pathway in HEK293 cells
M Nishikawa, S Nakano, H Nakao, K Sato, T Sugiyama, Y Akao, H Nagaoka, H Yamakawa, T Nagase, H Ueda
Cellular Signalling 2019
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway
K Kurmi, S Hitosugi, J Yu, F Boakye-Agyeman, EK Wiese, TR Larson, Q Dai, YJ Machida, Z Lou, L Wang, JC Boughey, SH Kaufmann, MP Goetz, LM Karnitz, T Hitosugi
Cell Metabolism 2018
Paradoxical counteraction by imatinib against cell death in myeloid progenitor 32D cells expressing p210BCR-ABL
M Takita, F Tsukahara, T Mishima, K Ieguchi, M Yamada, H Honda, Y Maru
Oncotarget 2018
The Molecular Basis of Human Cancer
WA Ricke, K Williams, J Wynder, G Palapattu, Y Wang, GR Cunha
The Molecular Basis of Human Cancer 2017
Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells
Q Li, Z Huang, M Gao, W Cao, Q Xiao, H Luo, W Feng
International journal of molecular sciences 2017
Pleckstrin homology domain of p210 BCR-ABL interacts with cardiolipin to regulate its mitochondrial translocation and subsequent mitophagy
K Shimasaki, M Watanabe-Takahashi, M Umeda, S Funamoto, Y Saito, N Noguchi, K Kumagai, K Hanada, F Tsukahara, Y Maru, N Shibata, M Naito, K Nishikawa
Genes to Cells 2017
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases
Y Dasgupta, M Koptyra, G Hoser, K Kantekure, D Roy, B Gornicka, M Nieborowska-Skorska, E Bolton-Gillespie, S Cerny-Reiterer, M Muschen, P Valent, MA Wasik, C Richardson, O Hantschel, H der Kuip, T Stoklosa, T Skorski
Blood 2016
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
B Linder, J Pinilla-Ibarz, K Sweet, G Corrales-Yepez, R Komrokji
OncoTargets and therapy 2016
Colocalization of cortactin and PH domain of BCR in HEK293T cells and its potential role in cell signaling
DS Gurianov, SV Antonenko, GD Telegeev
Biopolymers and Cell 2016
Mapk15 mediates bcr-abl1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation
D Colecchia, M Rossi, F Sasdelli, S Sanzone, A Strambi, M Chiariello
Autophagy 2015
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer
GA de Oliveira, LP Rangel, DC Costa, JL Silva
Frontiers in Oncology 2015
Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration–Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal
EM O'Connell, S Bennuru, C Steel, MA Dolan, TB Nutman
The Journal of Infectious Diseases 2015
Chromosomal Translocations and Genome Rearrangements in Cancer
JD Rowley, MM Beau, TH Rabbitts
2015
Kinase-Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors
CV Ichim
Stem Cells Translational Medicine 2014
Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
JM Drake, JK Lee, ON Witte
Molecular and cellular biology 2014
Myeloproliferative Disorders
B Meier, JH Burton
Emergency Medicine Clinics of North America 2014
Strategic therapeutic approaches to overcome emerging dual SRC/ABL kinase inhibitors resistances in chronic phase Ph positive chronic myeloid leukemia
R Rana, S Das, A Swami, D Pon, S Ramesh, SD Kumar
Asian Journal of Medical Sciences 2014
Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia
SB Foley, ZL Hildenbrand, AA Soyombo, JA Magee, Y Wu, KI Oravecz-Wilson, TS Ross
Cell Reports 2013
BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives
J Cui, R Fu, LH Zhou, SP Chen, GW Li, SX Qian, S Liu
Bioorganic & Medicinal Chemistry Letters 2013
Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog
JF Figueiredo, S Culver, E Behling-Kelly, M Breen, KR Friedrichs
Veterinary Clinical Pathology 2012
BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia
S Roy, HG Jørgensen, P Roy, MA el Baky, JV Melo, G Strathdee, TL Holyoake, C Bartholomew
British Journal of Haematology 2012
Effective killing of leukemia cells by the natural product OSW-1 through disruption of cellular calcium homeostasis
C Garcia-Prieto, KB Ahmed, Z Chen, Y Zhou, N Hammoudi, Y Kang, C Lou, Y Mei, Z Jin, P Huang
The Journal of biological chemistry 2012
Effector caspases and leukemia
Y Lu, GQ Chen
International Journal of Cell Biology 2011
Leukemias: Principles and Practice of Therapy
O Sala-Torra, JP Radich
Leukemias: Principles and Practice of Therapy 2011
c-Abl in Neurodegenerative Disease
SD Schlatterer, CM Acker, P Davies
Journal of Molecular Neuroscience 2011
Innovative technology for cancer risk analysis
S Tommas, K Danza, B Pilato, SD Summa
Annals of Oncology 2011
Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
MM Barcelos, MC Santos-Silva
Revista Brasileira de Hematologia e Hemoterapia 2011
BRIT1/MCPH1 Expression in Chronic Myeloid Leukemia and Its Regulation of the G2/M Checkpoint
C Giallongo, D Tibullo, PL Cava, A Branca, N Parrinello, P Spina, F Stagno, C Conticello, A Chiarenza, P Vigneri, GA Palumbo, FD Raimondo
Acta Haematologica 2011
Changing the Subcellular Location of the Oncoprotein Bcr-Abl Using Rationally Designed Capture Motifs
AS Dixon, JE Constance, T Tanaka, TH Rabbitts, CS Lim
Pharmaceutical Research 2011
Advances in Cancer Research
M Lemaire, S Deleu, ED Bruyne, EV Valckenborgh, E Menu, K Vanderkerken
Advances in Cancer Research Volume 110 2011
Interplay between Kinase Domain Autophosphorylation and F-Actin Binding Domain in Regulating Imatinib Sensitivity and Nuclear Import of BCR-ABL
M Preyer, P Vigneri, JY Wang, GS Wu
PloS one 2011
Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
P Valent
European Journal of Clinical Investigation 2010
The c-Abl tyrosine kinase stabilizes Pitx1 in the apoptotic response to DNA damage
T Yamaguchi, Y Miki, K Yoshida
Apoptosis 2010
Management of Chronic Myeloid Leukemia with BCR/ABL Inhibitors: Current Status and Future Perspectives
P Valent
Clinical medicine insights. Therapeutics 2010
Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring
M Zaliova, E Fronkova, K Krejcikova, K Muzikova, E Mejstrikova, J Stary, J Trka, J Zuna
Leukemia 2009
Proliferating cell nuclear antigen destabilizes c-Abl tyrosine kinase and regulates cell apoptosis in response to DNA damage
X He, C Wei, T Song, J Yuan, Y Zhang, Q Ma, W Shi, H Zhong
Apoptosis 2009
c-Abl Kinase Is Required for β 2 Integrin-Mediated Neutrophil Adhesion
L Cui, C Chen, T Xu, J Zhang, X Shang, J Luo, L Chen, X Ba, X Zeng
Journal of immunology (Baltimore, Md. : 1950) 2009
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
C Walz, NC Cross, RA van Etten, A Reiter
Leukemia 2008
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform
P Valent, T Lion, D Wolf, C Sillaber, H Agis, A Petzer, A Lang, P Kalhs, D Geissler, R Greil, W Linkesch, S Burgstaller, J Thaler, G Gastl
Wiener klinische Wochenschrift 2008
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
H Zhang, D Trachootham, W Lu, J Carew, FJ Giles, MJ Keating, RB Arlinghaus, P Huang
Leukemia 2008
An enhanced association of RACK1 with Abl in cells transfected with oncogenic ras
CC Huang, CH Liu, NN Chuang
The International Journal of Biochemistry & Cell Biology 2008
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease
P Valent
British Journal of Haematology 2008
TTK/Mps1 controls nuclear targeting of c-Abl by 14-3-3-coupled phosphorylation in response to oxidative stress
K Nihira, N Taira, Y Miki, K Yoshida
Oncogene 2008
Nuclear trafficking of pro-apoptotic kinases in response to DNA damage
K Yoshida
Trends in Molecular Medicine 2008
T cell survival and function requires the c-Abl tyrosine kinase
I Silberman, RV Sionov, V Zuckerman, S Haupt, Z Goldberg, A Strasser, ZS Ben-Sasson, M Baniyash, AJ Koleske, Y Haupt
Cell cycle (Georgetown, Tex.) 2008
Treatment of Intracerebral Glioblastomas with G422 Tumour Cell Vaccine in a Mouse Model
YH Ma, JB Yu, HP Yao, RY Zhan, JS Zheng
J INT MED RES 2008
Subcellular distribution of p210BCR-ABL in CML cell lines and primary CD34+ CML cells
H Patel, SB Marley, L Greener, MY Gordon
Leukemia 2007
Chronic myeloid leukaemia as a model of disease evolution in human cancer
JV Melo, DJ Barnes
Nature Reviews Cancer 2007
Enterovirus 71 triggering of neuronal apoptosis through activation of Abl-Cdk5 signalling
TC Chen, YK Lai, CK Yu, JL Juang
Cellular Microbiology 2007
ERK1/2 inactivation and p38 MAPK-dependent caspase activation during guanosine 5′-triphosphate-mediated terminal erythroid differentiation of K562 cells
MA Moosavi, R Yazdanparast, A Lotfi
The International Journal of Biochemistry & Cell Biology 2007
Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
P Valent
Biologics : targets & therapy 2007
Gag Influences Transformation by Abelson Murine Leukemia Virus and Suppresses Nuclear Localization of the v-Abl Protein
CR Yi, N Rosenberg
Journal of virology 2007
MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage
D Raina, R Ahmad, S Kumar, J Ren, K Yoshida, S Kharbanda, D Kufe
The EMBO Journal 2006
Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance
N Underhill-Day, A Pierce, SE Thompson, D Xenaki, AD Whetton, PJ Owen-Lynch
British Journal of Haematology 2006
Abl
A Pendergast, P Zipfel
AfCS-Nature Molecule Pages 2006
Differential effect of leukaemogenic tyrosine kinases on cell motility is governed by subcellular localisation
A Pierce, Y Lu, HG Hamzah, S Thompson, PJ Owen-Lynch, AD Whetton, E Spooncer
British Journal of Haematology 2006
Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2
H Patel, SB Marley, MY Gordon
Genes, Chromosomes and Cancer 2006
Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia
D Primo, J Flores, S Quijano, ML Sanchez, ME Sarasquete, J Pino-Montes, PI Gaarder, M Gonzalez, A Orfao
British Journal of Haematology 2006
Aberrant FHIT protein expression in classical Hodgkin’s lymphoma: a potential marker
P Zhao, AK Lam, YL Lu, M Zhong, LH Chen, XL Pu
Pathology 2006
Structural Basis for the Cytoskeletal Association of Bcr-Abl/c-Abl
O Hantschel, S Wiesner, T Güttler, CD Mackereth, LL Rix, Z Mikes, J Dehne, D Görlich, M Sattler, G Superti-Furga
Molecular Cell 2005
Stress and death: breaking up the c-Abl/14-3-3 complex in apoptosis
AM Pendergast
Nature Cell Biology 2005
JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage
K Yoshida, T Yamaguchi, T Natsume, D Kufe, Y Miki
Nature Cell Biology 2005
Philadelphia positive acute lymphoblastic leukaemia of childhood
LK Jones, V Saha
British Journal of Haematology 2005
TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS*
R Tibes, J Trent, R Kurzrock
Annual Review of Pharmacology and Toxicology 2005
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors
DR Veach, M Namavari, T Beresten, J Balatoni, M Minchenko, H Djaballah, RD Finn, B Clarkson, JG Gelovani, WG Bornmann, SM Larson
Nuclear Medicine and Biology 2005
Rho GTPases in Hematopoietic Cells
PB van Hennik, PL Hordijk
Antioxidants & Redox Signaling 2005
Oncogenes as Novel Targets for Cancer Therapy (Part I): Growth Factors and Protein Tyrosine Kinases
Z Zhang, M Li, ER Rayburn, DL Hill, R Zhang, H Wang
American Journal of PharmacoGenomics 2005
BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint
J Dierov, R Dierova, M Carroll
Cancer Cell 2004
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein
B Scappini, S Gatto, F Onida, C Ricci, V Divoky, WG Wierda, M Andreeff, L Dong, K Hayes, S Verstovsek, HM Kantarjian, M Beran
Cancer 2004
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation
N Orsolic, FJ Giles, H Gourdeau, M Golemovic, M Beran, J Cortes, EJ Freireich, H Kantarjian, S Verstovsek
British Journal of Haematology 2004
p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells
S Salesse, SJ Dylla, CM Verfaillie
Leukemia 2004
BCR/ABL activates mdm2 mRNA translation via the La antigen
R Trotta, T Vignudelli, O Candini, RV Intine, L Pecorari, C Guerzoni, G Santilli, MW Byrom, S Goldoni, LP Ford, MA Caligiuri, RJ Maraia, D Perrotti, B Calabretta
Cancer Cell 2003
Tyrosine Kinase Inhibitors as Cancer Therapy: Clinical Science Review
GL Nichols
Cancer Investigation 2003
The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains
M Stanglmaier, M Warmuth, I Kleinlein, S Reis, M Hallek
Leukemia 2003
Identification of new MHC-restriction elements for presentation of the p210BCR-ABL fusion region to human cytotoxic T lymphocytes
JY Sun, D Senitzer, SJ Forman, S Chatterjee, KK Wong
Cancer Immunology, Immunotherapy 2003
Bcr-Abl is a “Molecular Switch” for the Decision for Growth and Differentiation in Hematopoietic Stem Cells
T Era
International Journal of Hematology 2002
p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases
AM di Bacco, TG Cotter
British Journal of Haematology 2002
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
S Roumiantsev, NP Shah, ME Gorre, J Nicoll, BB Brasher, CL Sawyers, RA van Etten
Proceedings of the National Academy of Sciences 2002
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
A Klejman, L Rushen, A Morrione, A Slupianek, T Skorski
Oncogene 2002
Chronic myelogenous leukemia: mechanisms underlying disease progression
AS Shet, BN Jahagirdar, CM Verfaillie
Leukemia 2002
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells
B Scappini, F Onida, HM Kantarjian, L Dong, S Verstovsek, MJ Keating, M Beran
Cancer 2002
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
B Falini, DY Mason
Blood 2002
Mechanisms of Transformation by the BCR/ABL Oncogene
M Sattler, JD Griffin
International Journal of Hematology 2001
Molecular Biology of Chronic Myeloid Leukemia
Y Maru
International Journal of Hematology 2001
Philadelphia Chromosome–Positive Acute Lymphocytic Leukemia
JP Radich
Hematology/Oncology Clinics of North America 2001
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
TL Holyoake, X Jiang, HG Jorgensen, S Graham, MJ Alcorn, C Laird, AC Eaves, CJ Eaves
Blood 2001
Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation
B Bruecher-Encke, JD Griffin, BG Neel, U Lorenz
Leukemia 2001
Adhesion to fibronectin selectively protects Bcr-Abl+cells from DNA damage–induced apoptosis
H van der Kuip, AW Goetz, C Miething, J Duyster, WE Aulitzky
Blood 2001
Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells
I Gaston, PE Stenberg, A Bhat, BJ Druker
Experimental Hematology 2000
c-Abl expression in oral squamous cell carcinomas
T Yanagawa, H Harada, S Iwasa, K Tabuchi, K Omura, H Suzuki, H Yusa, K Yamagata, K Onizawa, T Ishii, H Yoshida
Oral Oncology 2000
Light Microscopic Detection of BCR-ABL Transcripts after In-Cell RT-PCR: Fusion Gene Expression Might Correlate with Clinical Evolution of Chronic Myeloid Leukemia
G Balatzenko, M Guenova
Leukemia & Lymphoma 2000
Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins
E Laurent, M Talpaz, M Wetzler, R Kurzrock
Leukemia 2000
Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis
AD Bacco, K Keeshan, SL McKenna, TG Cotter
The oncologist 2000
Cycling, stressed-out and nervous: cellular functions of c-Abl
RA van Etten
Trends in Cell Biology 1999
Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics
Branford, Hughes, Rudzki
British Journal of Haematology 1999
ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5
D Smedley, A Demiroglu, M Abdul-Rauf, C Heath, C Cooper, J Shipley, NC Cross
Neoplasia (New York, N.Y.) 1999
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein
N Takeda, M Shibuya, Y Maru
Proceedings of the National Academy of Sciences 1999
BCR Binds to the Xeroderma Pigmentosum Group B Protein
Y Maru, T Kobayashi, K Tanaka, M Shibuya
Biochemical and Biophysical Research Communications 1999
Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins
PA Skourides, SA Perera, R Ren
Oncogene 1999
BCR/ABL mRNA and the P210BCR/ABL Protein Are Downmodulated by Interferon- in Chronic Myeloid Leukemia Patients
F Pane, I Mostarda, C Selleri, R Salzano, AM Raiola, L Luciano, G Saglio, B Rotoli, F Salvatore
Blood 1999
Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors
T Jonuleit, C Peschel, R Schwab, H der Kuip, E Buchdunger, T Fischer, C Huber, WE Aulitzky
British Journal of Haematology 1998
Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia
C Eaves, J Cashman, A Eaves
Leukemia Research 1998
BIOLOGY OF CHRONIC MYELOGENOUS LEUKEMIA
CM Verfaillie
Hematology/Oncology Clinics of North America 1998
The Effect of Interferon-α on Beta-1 Integrin Mediated Adhesion and Growth Regulation in Chronic Myelogenous Leukemia
R Bhatia, CM Verfaillie
Leukemia & Lymphoma 1998
Expression and Function of the Megakaryocyte Growth and Development Factor Receptor in Acute Myeloid Leukemia Blasts
M Wetzler, SH Bernstein, H Baumann, KM Fries, C Stewart, L Blumenson, MR Baera, GP Herziga, CD Bloomfielda, JL Slack
Leukemia & Lymphoma 1998
Acute Leukemias VII
W Hiddemann, T Büchner, B Wörmann, J Ritter, U Creutzig, M Keating, W Plunkett
1998
The C-Terminus of c-Abl Is Required for Proliferation and Viability Signaling in a c-Abl/Erythropoietin Receptor Fusion Protein
K Okuda, A DAndrea, RA Etten, JD Griffin
Blood 1998
Suppression of Cell Proliferation and the Expression of abcr-abl Fusion Gene and Apoptotic Cell Death in a New Human Chronic Myelogenous Leukemia Cell Line, KT-1, by Interferon-α
K Yanagisawa, H Yamauchi, M Kaneko, H Kohno, H Hasegawa, S Fujita
Blood 1998
Phosphorylation of Enabled by the Drosophila Abelson Tyrosine Kinase Regulates the In Vivo Function and Protein-Protein Interactions of Enabled
AR Comer, SM Ahern-Djamali, JL Juang, PD Jackson, FM Hoffmann
Molecular and cellular biology 1998
BCR/ABL induces multiple abnormalities of cytoskeletal function
R Salgia, JL Li, DS Ewaniuk, W Pear, E Pisick, SA Burky, T Ernst, M Sattler, LB Chen, JD Griffin
Journal of Clinical Investigation 1997
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
M Sattler, R Salgia
Cytokine & Growth Factor Reviews 1997
Abl expression in human fetal and adult tissues, tumours and tumour microvessels
AJ O'Neill, TG Cotter, JM Russell, EF Gaffney
The Journal of Pathology 1997
Signal transduction by wild-type and leukemogenic Abl proteins
AB Raitano, YE Whang, CL Sawyers
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1997
The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation
L Kadlec, AM Pendergast
Proceedings of the National Academy of Sciences 1997
The murine AIDS virus Gag precursor protein binds to the SH3 domain of c-Abl
P Dupraz, N Rebai, SJ Klein, N Beaulieu, P Jolicoeur
Journal of virology 1997
STEM CELLS IN CHRONIC MYELOGENOUS LEUKEMIA
CM Verfaillie
Hematology/Oncology Clinics of North America 1997
Apoptosis in Chronic Myelogenous Leukemia: Studies of Stage-Specific Differences
H Gisslinger, R Kurzrock, M Wetzler, S Tucker, H Kantarjian, B Robertson, M Talpaz
Leukemia & Lymphoma 1997
The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-independent Mechanism and Phosphorylates the Grb2-binding Site of Bcr
M Warmuth, M Bergmann, A Prieß, K Häuslmann, B Emmerich, M Hallek
The Journal of biological chemistry 1997
Acute Leukemias VI
T Büchner, G Schellong, J Ritter, U Creutzig, W Hiddemann, B Wörmann
1997
Naturally Processed Tissue- and Differentiation Stage-Specific Autologous Peptides Bound by HLA Class I and II Molecules of Chronic Myeloid Leukemia Blasts
KP Papadopoulos, N Suciu-Foca, CS Hesdorffer, S Tugulea, A Maffei, PE Harris
Blood 1997
Chronic myelogenous leukemia: an update on the biological findings and therapeutic approaches
A Ferrajoli, M Fizzotti, AM Liberati, F Grignani
Critical Reviews in Oncology/Hematology 1996
The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products
ST Wen, PK Jackson, RA van Etten
The EMBO Journal 1996
BCR/ABL and leukemia
A Butturini, RB Arlinghaus, RP Gale
Leukemia Research 1996
Treatment of marrow stroma with interferon-alpha restores normal beta 1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1 alpha
R Bhatia, PB McGlave, CM Verfaillie
Journal of Clinical Investigation 1995
Increased neutrophil respiratory burst in bcr-null mutants
JW Voncken, H Schaick, V Kaartinen, K Deemer, T Coates, B Landing, P Pattengale, O Dorseuil, GM Bokoch, J Groffen, N Heisterkamp
Cell 1995
Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin
M Wetzler, M Talpaz, G Yee, SA Stass, RA van Etten, M Andreeff, AM Goodacre, HD Kleine, RK Mahadevia, R Kurzrock
Proceedings of the National Academy of Sciences 1995
Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function
R Bhatia, EA Wayner, PB McGlave, CM Verfaillie
Journal of Clinical Investigation 1994
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies
M Talpaz, Z Estrov, H Kantarjian, S Ku, A Foteh, R Kurzrock
Journal of Clinical Investigation 1994
Cell Death in the Myeloid Lineage
TG Cotter, RS Fernandes, S Verhaegln, JV McCarthy
Immunological Reviews 1994
The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity
RA van Etten, PK Jackson, D Baltimore, MC Sanders, PT Matsudaira, PA Janmey
The Journal of Cell Biology 1994
Acute Leukemias
T Büchner, G Schellong, W Hiddemann, D Urbanitz, J Ritter
1987

← Previous 1 2 3 4 5 6 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
67 readers on Mendeley
See more details